SAFETY DATA SHEET according to Regulation (EC) No. 1907/2006



1/11

SPARTICUS XPRO

Version 2 / GB Revision Date: 19.05.2014 102000024997 Print Date: 19.05.2014

SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1 Product identifier

Trade name SPARTICUS XPRO

Product code (UVP) 79994672

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use Fungicide

1.3 Details of the supplier of the safety data sheet

Supplier Bayer CropScience Limited

230 Cambridge Science Park

Milton Road Cambridge

Cambridgeshire CB4 0WB

United Kingdom

Telephone +44(0)1223 226500 Telefax +44(0)1223 426240

Responsible Department Email: ukinfo@bayercropscience.com

1.4 Emergency telephone no.

Emergency telephone no. 0800-220876 (UK 24 hr)

+44(0)1635-563000 (Overseas 24 hr)

SECTION 2: HAZARDS IDENTIFICATION

2.1 Classification of the substance or mixture

Classification in accordance with Regulation (EC) No 1272/2008 on classification, labelling and packaging of substances and mixtures, as amended.

Skin sensitisation: Category 1

H317 May cause an allergic skin reaction.

Reproductive toxicity: Category 2

H361d Suspected of damaging the unborn child.

Acute toxicity: Category 4

H302 Harmful if swallowed.

Acute aquatic toxicity: Category 1

H400 Very toxic to aquatic life.

Chronic aquatic toxicity: Category 1

H410 Very toxic to aquatic life with long lasting effects.

Classification according to EU Directives 67/548/EEC or 1999/45/EC

Xn Harmful, R22

R43

Repr.Cat.3, R63

N Dangerous for the environment, R51/53

2.2 Label elements

Labelling in accordance with Regulation (EC) No 1272/2008 on classification, labelling and packaging of substances and mixtures, as amended.

SAFETY DATA SHEET according to Regulation (EC) No. 1907/2006



2/11

SPARTICUS XPRO

Version 2 / GB Revision Date: 19.05.2014 102000024997 Print Date: 19.05.2014

Hazard label for supply/use required.

Hazardous components which must be listed on the label:

- Bixafen
- Prothioconazole
- Tebuconazole







Signal word: Warning Hazard statements

H302 Harmful if swallowed.

H317 May cause an allergic skin reaction.H361d Suspected of damaging the unborn child.

H410 Very toxic to aquatic life with long lasting effects.

EUH401 To avoid risks to human health and the environment, comply with the instructions for

use.

Precautionary statements

P280 Wear protective gloves/protective clothing/eye protection/face protection.

P308 + P313 IF exposed or concerned: Get medical advice/attention.

P501 Dispose of contents/container to a licensed hazardous-waste disposal contractor or

collection site except for empty clean containers which can be disposed of as non-

hazardous waste.

2.3 Other hazards

No other hazards known.

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.2 Mixtures

Chemical nature

Emulsifiable concentrate (EC)

Bixafen/Prothioconazole/Tebuconazole 75:110:90 g/l

Hazardous components

R-phrase(s) according to EC directive 67/548/EEC

Hazard statements according to Regulation (EC) No. 1907/2006

Name	CAS-No./	Classification		Conc. [%]
	EC-No.	EC Directive 67/548/EEC	Regulation (EC) No 1272/2008	
Bixafen	581809-46-3	N; R50/53	Aquatic Acute 1, H400 Aquatic Chronic 1, H410	7.40
Prothioconazole	178928-70-6 605-841-2	N; R51/53	Aquatic Chronic 2, H411	10.80
Tebuconazole	107534-96-3 403-640-2	Repr.Cat.3 R63 Xn; R22 N; R51/53	Repr. 2, H361d Acute Tox. 4, H302 Aquatic Chronic 2, H411	8.90

SAFETY DATA SHEET according to Regulation (EC) No. 1907/2006



SPARTICUS XPRO

3/11 Version 2/GB Revision Date: 19.05.2014 102000024997 Print Date: 19.05.2014

2-Ethylhexanol propylene ethyleneglycol ether	64366-70-7 613-582-1	R52/53	Aquatic Chronic 3, H412	> 1.00 - < 25.00
N,N-Dimethyl decanamide	14433-76-2 238-405-1	Xi; R36/38	Skin Irrit. 2, H315 Eye Irrit. 2, H319 Aquatic Chronic 3, H412	> 10.00

Further information

For the full text of the R-phrases/ Hazard statements mentioned in this Section, see Section 16.

SECTION 4: FIRST AID MEASURES

4.1 Description of first aid measures

General advice Move out of dangerous area. Place and transport victim in stable

position (lying sideways). Remove contaminated clothing immediately

and dispose of safely.

Inhalation Move to fresh air. Keep patient warm and at rest. Call a physician or

poison control center immediately.

Skin contact Wash off thoroughly with plenty of soap and water, if available with

polyethyleneglycol 400, subsequently rinse with water. If symptoms

persist, call a physician.

Eye contact Rinse immediately with plenty of water, also under the eyelids, for at

> least 15 minutes. Remove contact lenses, if present, after the first 5 minutes, then continue rinsing eye. Get medical attention if irritation

develops and persists.

Rinse mouth. Do NOT induce vomiting. Call a physician or poison Ingestion

control center immediately.

4.2 Most important symptoms and effects, both acute and delayed

Symptoms No symptoms known or expected.

4.3 Indication of any immediate medical attention and special treatment needed

Treat symptomatically. In case of ingestion gastric lavage should be **Treatment**

> considered in cases of significant ingestions only within the first 2 hours. However, the application of activated charcoal and sodium

sulphate is always advisable. There is no specific antidote.

SECTION 5: FIREFIGHTING MEASURES

5.1 Extinguishing media

Suitable Use water spray, alcohol-resistant foam, dry chemical or carbon

dioxide.

Unsuitable High volume water jet

SAFETY DATA SHEET according to Regulation (EC) No. 1907/2006



4/11

SPARTICUS XPRO

Version 2 / GB Revision Date: 19.05.2014 102000024997 Print Date: 19.05.2014

5.2 Special hazards arising from the substance or mixture

In the event of fire the following may be released:, Hydrogen chloride (HCl), Hydrogen cyanide (hydrocyanic acid), Hydrogen fluoride, Carbon monoxide (CO), Sulphur oxides, Nitrogen oxides (NOx)

5.3 Advice for firefighters

Special protective equipment for fire-fighters

In the event of fire and/or explosion do not breathe fumes. In the event of fire, wear self-contained breathing apparatus.

Further information

Contain the spread of the fire-fighting media. Do not allow run-off from fire fighting to enter drains or water courses.

SECTION 6: ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures

Precautions Avoid contact with spilled product or contaminated surfaces. Use

personal protective equipment.

6.2 Environmental precautions

Do not allow to get into surface water, drains and ground water. If spillage enters drains leading to sewage works inform local water company immediately. If spillage enters rivers or watercourses, inform the Environment Agency (emergency telephone number 0800

807060).

6.3 Methods and materials for containment and cleaning up

Methods for cleaning up Soak up with inert absorbent material (e.g. sand, silica gel, acid

binder, universal binder, sawdust). Clean contaminated floors and objects thoroughly, observing environmental regulations. Keep in

suitable, closed containers for disposal.

6.4 Reference to other

sections

Information regarding safe handling, see section 7.

Information regarding personal protective equipment, see section 8.

Information regarding waste disposal, see section 13.

SECTION 7: HANDLING AND STORAGE

7.1 Precautions for safe handling

Advice on safe handling
No specific precautions required when handling unopened

packs/containers; follow relevant manual handling advice. Ensure

adequate ventilation.

Advice on protection against fire and explosion

No special precautions required.

Hygiene measures Avoid contact with skin, eyes and clothing. Keep working clothes

separately. Wash hands immediately after work, if necessary take a shower. Remove soiled clothing immediately and clean thoroughly before using again. Garments that cannot be cleaned must be

destroyed (burnt).

7.2 Conditions for safe storage, including any incompatibilities

SAFETY DATA SHEET according to Regulation (EC) No. 1907/2006



5/11

SPARTICUS XPRO

Version 2/GB Revision Date: 19.05.2014 102000024997 Print Date: 19.05.2014

Requirements for storage areas and containers

Store in original container. Keep containers tightly closed in a dry, cool and well-ventilated place. Store in a place accessible by authorized

persons only. Keep away from direct sunlight.

7.3 Specific end uses Refer to the label and/or leaflet.

SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1 Control parameters

Components	CAS-No.	Control parameters	Update	Basis
Bixafen	581809-46-3	0.6 mg/m3 (OES BCS)		OES BCS*
Prothioconazole	178928-70-6	1.4 mg/m3 (TWA)		OES BCS*
Tebuconazole	107534-96-3	0.2 mg/m3 (TWA)		OES BCS*

^{*}OES BCS: Internal Bayer CropScience "Occupational Exposure Standard"

8.2 Exposure controls

Refer to COSHH assessment (Control of Substances Hazardous to Health (Amendment) Regulations 2004). Engineering controls should be used in preference to personal protective equipment wherever practicable. Refer also to COSHH Essentials.

Personal protective equipment

In normal use and handling conditions please refer to the label and/or leaflet. In all other cases the following recommendations would apply.

Respiratory protection Wear respirator with an organic vapours and gas filter mask

(protection factor 10) conforming to EN140 type A or equivalent. Respiratory protection should only be used to control residual risk of short duration activities, when all reasonably practicable steps have been taken to reduce exposure at source e.g. containment and/or local extract ventilation. Always follow respirator manufacturer's

instructions regarding wearing and maintenance.

Wear CE Marked (or equivalent) nitrile rubber gloves (minimum Hand protection

> thickness of 0,4 mm). Wash when contaminated and dispose of when contaminated inside, when perforated or when contamination on the outside cannot be removed. Wash hands frequently and always before eating, drinking, smoking or using the toilet.

Eye protection Wear goggles (conforming to EN166, Field of Use = 5 or equivalent).

Wear standard coveralls and Category 3 Type 4 suit. Skin and body protection

If there is a risk of significant exposure, consider a higher protective

type suit.

Wear two layers of clothing wherever possible. Polyester/cotton or cotton overalls should be worn under chemical protection suit and

should be professionally laundered frequently.

If chemical protection suit is splashed, sprayed or significantly contaminated, decontaminate as far as possible, then carefully remove and dispose of as advised by manufacturer.

SAFETY DATA SHEET according to Regulation (EC) No. 1907/2006



6/11

SPARTICUS XPRO

Version 2 / GB Revision Date: 19.05.2014 102000024997 Print Date: 19.05.2014

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1 Information on basic physical and chemical properties

Form Liquid, clear to slightly turbid

ColourbrownOdouraromatic

pH 4.5 - 6.5 at 1 % (23 °C) (deionized water)

Flash point 148 °C

Density 1.02 g/cm³ at 20 °C

Partition coefficient: n-

octanol/water

Bixafen: log Pow: 3.3 at 40 °C

Prothioconazole: log Pow: 3.82 at 20 °C

Tebuconazole: log Pow: 3.7

9.2 Other information Further safety related physical-chemical data are not known.

SECTION 10: STABILITY AND REACTIVITY

10.1 Reactivity

Thermal decomposition Stable under normal conditions.

10.2 Chemical stability Stable under recommended storage conditions.

10.3 Possibility ofNo hazardous reactions when stored and handled according to prescribed instructions.

processed metactions

10.4 Conditions to avoid Extremes of temperature and direct sunlight.

10.5 Incompatible materials Store only in the original container.

10.6 Hazardous

decomposition products

No decomposition products expected under normal conditions of use.

SECTION 11: TOXICOLOGICAL INFORMATION

11.1 Information on toxicological effects

Acute oral toxicity LD50 (rat) 2,000 mg/kg

Test conducted with a similar formulation.

Acute dermal toxicity LD50 (rat) > 2,000 mg/kg

Test conducted with a similar formulation.

Skin irritation No skin irritation (rabbit)

Test conducted with a similar formulation.

Eye irritation No eye irritation (rabbit)

Test conducted with a similar formulation.

Sensitisation Sensitising (mouse)

OECD Test Guideline 429, local lymph node assay (LLNA)

Test conducted with a similar formulation.

SAFETY DATA SHEET according to Regulation (EC) No. 1907/2006



7/11

SPARTICUS XPRO

Version 2 / GB Revision Date: 19.05.2014 102000024997 Print Date: 19.05.2014

Assessment repeated dose toxicity

Bixafen did not cause specific target organ toxicity in experimental animal studies.

Prothioconazole did not cause specific target organ toxicity in experimental animal studies.

Tebuconazole did not cause specific target organ toxicity in experimental animal studies.

Assessment Mutagenicity

Bixafen was not mutagenic or genotoxic in a battery of in vitro and in vivo tests.

Prothioconazole was not mutagenic or genotoxic based on the overall weight of evidence in a battery of in vitro and in vivo tests.

Tebuconazole was not mutagenic or genotoxic in a battery of in vitro and in vivo tests.

Assessment Carcinogenicity

Bixafen was not carcinogenic in lifetime feeding studies in rats and mice.

Prothioconazole was not carcinogenic in lifetime feeding studies in rats and mice.

Tebuconazole caused at high dose levels an increased incidence of tumours in mice in the following organ(s): liver. The mechanism of tumour formation is not considered to be relevant to man.

Assessment toxicity to reproduction

Bixafen did not cause reproductive toxicity in a two-generation study in rats.

Prothioconazole caused reproduction toxicity in a two-generation study in rats only at dose levels also toxic to the parent animals. The reproduction toxicity seen with Prothioconazole is related to parental toxicity.

Tebuconazole caused reproduction toxicity in a two-generation study in rats only at dose levels also toxic to the parent animals. The reproduction toxicity seen with Tebuconazole is related to parental toxicity.

Assessment developmental toxicity

Bixafen did not cause developmental toxicity in rats and rabbits.

Prothioconazole caused developmental toxicity only at dose levels toxic to the dams. The developmental effects seen with Prothioconazole are related to maternal toxicity.

Tebuconazole caused developmental toxicity only at dose levels toxic to the dams. Tebuconazole caused an increased incidence of post implantation losses, an increased incidence of non-specific malformations.

SECTION 12: ECOLOGICAL INFORMATION

12.1 Toxicity

Toxicity to fish LC50 (Oncorhynchus mykiss (rainbow trout)) 1.55 mg/l

Exposure time: 96 h

Test conducted with a similar formulation.

Toxicity to aquatic

EC50 (Water flea (Daphnia magna)) 5.5 mg/l

invertebrates Exposure time: 48 h

Test conducted with a similar formulation.

Chronic toxicity to aquatic

invertebrates

NOEC (Daphnia): 0.01 mg/l

Exposure time: 21 d

The value mentioned relates to the active ingredient tebuconazole.

Toxicity to aquatic plants IC50 (Pseudokirchneriella subcapitata) 1.93 mg/l

Growth rate; Exposure time: 72 h

Test conducted with a similar formulation. EC50 (Skeletonema costatum) 0.046 mg/l

SAFETY DATA SHEET according to Regulation (EC) No. 1907/2006



8/11

SPARTICUS XPRO

Version 2 / GB Revision Date: 19.05.2014 102000024997 Print Date: 19.05.2014

Growth rate; Exposure time: 72 h

The value mentioned relates to the active ingredient prothioconazole.

12.2 Persistence and degradability

Biodegradability Bixafen:

not rapidly biodegradable

Prothioconazole:

not rapidly biodegradable

Tebuconazole:

not rapidly biodegradable

Koc Bixafen: Koc: 3869

Prothioconazole: Koc: 1765; log Koc: < 3

Tebuconazole: Koc: 769

12.3 Bioaccumulative potential

Bioaccumulation Bixafen: Bioconcentration factor (BCF) 695

Does not bioaccumulate.

Prothioconazole: Bioconcentration factor (BCF) 19

Does not bioaccumulate.

Tebuconazole: Bioconcentration factor (BCF) 35 - 59

Does not bioaccumulate.

12.4 Mobility in soil

Mobility in soil Bixafen: Slightly mobile in soils

Prothioconazole: Slightly mobile in soils Tebuconazole: Slightly mobile in soils

12.5 Results of PBT and vPvB assessment

PBT and vPvB assessment Bixafen: This substance is not considered to be persistent,

bioaccumulative and toxic (PBT). This substance is not considered to be

very persistent and very bioaccumulative (vPvB).

Prothioconazole: This substance is not considered to be very persistent and very bioaccumulative (vPvB). This substance is not considered to

be persistent, bioaccumulative and toxic (PBT).

Tebuconazole: This substance is not considered to be persistent, bioaccumulative and toxic (PBT). This substance is not considered to be

very persistent and very bioaccumulative (vPvB).

12.6 Other adverse effects

Additional ecological

information

No other effects to be mentioned.

SECTION 13: DISPOSAL CONSIDERATIONS

13.1 Waste treatment methods

Product In accordance with current regulations and, if necessary, after

consultation with the site operator and/or with the responsible authority, the product may be taken to a waste disposal site or incineration plant. Advice may be obtained from the local waste regulation authority (part

of the Environment Agency in the UK).

Contaminated packaging Small containers (< 10 l or < 10 kg) should be rinsed thoroughly using

an integrated pressure rinsing device, or, by manually rinsing three

times.

Add washings to sprayer at time of filling.

SAFETY DATA SHEET according to Regulation (EC) No. 1907/2006



9/11

SPARTICUS XPRO

Version 2 / GB Revision Date: 19.05.2014 102000024997 Print Date: 19.05.2014

Dispose of empty and cleaned packaging safely.

Large containers (> 25 l or > 25 kg) should not be rinsed or re-used for

any other purpose.

Return large containers to supplier.

Follow advice on product label and/or leaflet.

Waste key for the unused

product

020108 agrochemical waste containing dangerous substances

SECTION 14: TRANSPORT INFORMATION

ADR/RID/ADN

14.1 UN number 3082

14.2 Proper shipping name ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(BIXAFEN SOLUTION)

This classification is in principle not valid for carriage by tank vessel on inland waterways. Please refer to the manufacturer for further information.

IMDG

14.1 UN number **3082**

14.2 Proper shipping name ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(BIXAFEN SOLUTION)

14.3 Transport hazard class(es) 9
14.4 Packing group III
14.5 Marine pollutant YES

IATA

14.1 UN number **3082**

14.2 Proper shipping name ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(BIXAFEN SOLUTION)

14.3 Transport hazard class(es) 9
14.4 Packing group III
14.5 Environm. Hazardous Mark YES

UK 'Carriage' Regulations

14.1 UN number 3082

14.2 Proper shipping name ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(BIXAFEN SOLUTION)

14.3 Transport hazard class(es)914.4 Packing groupIII14.5 Environm. Hazardous MarkYESEmergency action code3Z

14.6 Special precautions for user

See sections 6 to 8 of this Safety Data Sheet.

SAFETY DATA SHEET according to Regulation (EC) No. 1907/2006



10/11

SPARTICUS XPRO

Version 2 / GB Revision Date: 19.05.2014 102000024997 Print Date: 19.05.2014

14.7 Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

No transport in bulk according to the IBC Code.

SECTION 15: REGULATORY INFORMATION

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture UK and Northern Ireland Regulatory References

This material may be subject to some or all of the following regulations (and any subsequent amendments). Users must ensure that any uses and restrictions as indicated on the label and/or leaflet are followed.

Transport

Carriage of Dangerous Goods and Use of Transportable Pressure Equipment Regulations 2009 (SI 2009 No 1348)

Merchant Shipping (Dangerous Goods and Marine Pollutants) Regulations 1997 (SI 1997 No 2367) Air Navigation Dangerous Goods Regulations 2002 (SI 2002 No 2786)

Supply and Use

Chemical (Hazard Information and Packaging for Supply) Regulations 2009 (SI 2009 No 716) Chemical (Hazard Information and Packaging for Supply) (Northern Ireland) Regulations 2009 Control of Substances Hazardous to Health Regulations 2002 (SI 2002 No 2677) EH40 Occupational Exposure Limits - Table 1 List of approved workplace exposure limits Control of Pesticide Regulations 1986

Dangerous Substances and Explosive Atmospheres Regulations 2002

Waste Treatment

Environmental Protection Act 1990. Part II

Environmental Protection (Duty of Care) Regulations 1991

The Waste Management Licensing Regulations 1994 (as amended)

Hazardous Waste Regulations 2005 (Replacing Special Waste Regulations 1996 as amended)

Landfill Directive

Regulation on Substances That Deplete the Ozone Layer 1994 (EEC/3093/94)

Water Resources Act 1991

Anti-Pollution Works Regulations 1999

Further information

WHO-classification: II (Moderately hazardous)

15.2 Chemical Safety Assessment

A chemical safety assessment is not required.

SECTION 16: OTHER INFORMATION

Text of R-phrases mentioned in Section 3

R22	Harmful if swallowed.
R36/38	Irritating to eyes and skin.

R50/53 Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic

environment.

R51/53 Toxic to aquatic organisms, may cause long-term adverse effects in the aquatic

environment.

R52/53 Harmful to aquatic organisms, may cause long-term adverse effects in the aquatic

environment.

SAFETY DATA SHEET according to Regulation (EC) No. 1907/2006



11/11

SPARTICUS XPRO

Version 2 / GB Revision Date: 19.05.2014 102000024997 Print Date: 19.05.2014

R63 Possible risk of harm to the unborn child.

Text of the hazard statements mentioned in Section 3

H302	Harmful if swallowed.
H315	Causes skin irritation.
H319	Causes serious eye irritation.
H361d	Suspected of damaging the unborn child.
H400	Very toxic to aquatic life.
H410	Very toxic to aquatic life with long lasting effects.
H411	Toxic to aquatic life with long lasting effects.
H412	Harmful to aquatic life with long lasting effects.

The above information is intended to give general health and safety guidance on the storage and transport of the product.

It is not intended to apply to the use of the product for which purposes the product label and any appropriate technical usage literature available should be consulted and any relevant licenses, consents or approvals complied with.

The requirements or recommendations of any relevant site or working procedure, system or policy in force or arising from any risk assessment involving the substance or product should take precedence over any of the guidance contained in this safety data sheet where there is a difference in the information given.

The information provided in this safety data sheet is accurate at the date of publication and will be updated as and when appropriate.

No liability will be accepted for any injury, loss or damage resulting from any failure to take account of information or advice contained in this safety data sheet.

Reason for Revision: Section 12. Ecological information. Safety Data Sheet according to

Regulation (EU) No. 453/2010.

Changes since the last version are highlighted in the margin. This version replaces all previous versions.